{"id":"levocetirizine-oral-solution","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Somnolence"},{"rate":"5-8","effect":"Headache"},{"rate":"3-5","effect":"Fatigue"},{"rate":"2-4","effect":"Dry mouth"},{"rate":"2-3","effect":"Pharyngitis"}]},"_chembl":{"chemblId":"CHEMBL1201191","moleculeType":"Small molecule","molecularWeight":"388.90"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levocetirizine is the active R-enantiomer of cetirizine, a second-generation antihistamine that selectively antagonizes peripheral H1 receptors. By blocking histamine binding to H1 receptors on mast cells, basophils, and endothelial cells, it prevents the release and effects of histamine, thereby reducing allergic symptoms such as itching, urticaria, and rhinitis without significant central nervous system penetration.","oneSentence":"Levocetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:54.712Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis (seasonal and perennial)"},{"name":"Chronic urticaria"},{"name":"Allergic conjunctivitis"}]},"trialDetails":[{"nctId":"NCT04699604","phase":"PHASE3","title":"A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)","status":"RECRUITING","sponsor":"Bridgette Jones","startDate":"2021-04-28","conditions":"Allergic Asthma","enrollment":300},{"nctId":"NCT01392859","phase":"PHASE2, PHASE3","title":"Characterization of the Role of Histamine in Children With Asthma","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2011-06","conditions":"Asthma, Allergic Asthma, Non-allergic Asthma","enrollment":211},{"nctId":"NCT01622283","phase":"PHASE1","title":"Pharmacokinetic Study of Levocetirizine Oral Solution","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-05-02","conditions":"Rhinitis, Allergic, Perennial and Seasonal","enrollment":20},{"nctId":"NCT01563081","phase":"PHASE3","title":"Safety Study of Levocetirizine Oral Solution for Japanese Pediatrics","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-04","conditions":"Rhinitis","enrollment":60},{"nctId":"NCT00152412","phase":"PHASE2","title":"Open Study to Evaluate the Safety of Levocetirizine in Young Children (2 - 6 Years) Suffering From Allergic Rhinitis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-06","conditions":"Allergic Rhinitis","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xyzal"],"phase":"marketed","status":"active","brandName":"Levocetirizine oral solution","genericName":"Levocetirizine oral solution","companyName":"UCB Pharma","companyId":"ucb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levocetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses. Used for Allergic rhinitis (seasonal and perennial), Chronic urticaria, Allergic conjunctivitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}